[Clinical trial of a new topical anti-histamine agent histimet in the treatment of seasonal allergic rhinoconjunctivitis].

21 patients with seasonal allergic rhinoconjunctivitis (SAC) entered the trial of a new topical antihistamine drug histimet (levocabastine). The drug is available as a nasal spray and eye drops. The relief of the main symptoms of SAC occurred 15-20 min after histimet introduction into the nose or eye. The effect of a single procedure lasted for 12 hours. Regression of SAC basic symptoms continued for 7 days after using histimet. A significant improvement of life quality was observed. Good effect achieved in 90% of the patients characterizes histimet as an effective new modality in SAC management.